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Introduction: Sepsis is the leading cause of acute kidney injury (AKI) in critically ill patients. The Kidney in
Sepsis and Septic Shock (Kid-SSS) study evaluated the value of proenkephalin A 119-159 (penkid)—a sensitive
biomarker of glomerular function, drawn within 24 hours upon intensive care unit (ICU) admission and
analyzed using a chemiluminescence immunoassay—for kidney events in sepsis and septic shock.
Methods: The Kid-SSS study was a substudy of Adrenomedullin and Outcome in Severe Sepsis and
Septic Shock (AdrenOSS) (NCT02393781), a prospective, observational, multinational study including 583
patients admitted to the intensive care unit with sepsis or septic shock and a validation cohort of 525
patients from the French and euRopean Outcome reGistry in Intensive Care Units (FROG-ICU) study. The
primary endpoint was major adverse kidney events (MAKEs) at day 7, composite of death, renal
replacement therapy, and persistent renal dysfunction. The secondary endpoints included AKI, transient
AKI, worsening renal function (WRF), and 28-day mortality.
Results: Median age was 66 years (interquartile range 55–75), and 28-day mortality was 22% (95% conﬁdence
interval [CI] 19%25%). Of the patients, 293 (50.3%) were in shock upon ICU admission. Penkid was signiﬁcantly
elevated in patientswithMAKEs, persistent AKI, andWRF (median¼ 65 [IQR¼ 45–106] vs. 179 [114–242]; 53 [39–
70] vs. 133 [79–196] pmol/l; and 70 [47–121] vs. 174 [93–242] pmol/l, all P < 0.0001), also after adjustment for
confounding factors (adjustedodds ratio¼3.3 [95%CI¼1.8–6.0], 3.9 [95%CI¼2.1–7.2], and3.4 [95%CI¼1.9–6.2],
all P< 0.0001). Penkid increase preceded elevation of serum creatinine withWRF andwas low in renal recovery.
Conclusion: Admission penkid concentration was associated with MAKEs, AKI, and WRF in a timely
manner in septic patients.
Kidney Int Rep (2018) 3, 1424–1433; https://doi.org/10.1016/j.ekir.2018.08.006
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A KI is a frequent condition in critically ill patients,with considerable impact on both short- and long-
term outcome including morbidity, mortality, and
long-term loss of kidney function.1,2 However, its early
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detection remains challenging due to poor sensitivity
or speciﬁcity of current standard biomarkers (i.e.
serum creatinine and urine output).3–6 Implementation
of novel biomarkers that permit a reliable AKI risk
stratiﬁcation for ICU patients would allow developing
early efﬁcient management strategies with potential
positive impact on patient outcome.7 The use of bio-
markers of kidney injury or damage has shown con-
ﬂicting results with respect to AKI prediction, mostly
due to speciﬁcity issues and uncoupling between kid-
ney damage and loss of renal function.4,8
The ﬁltration marker penkid has recently been pro-
posed as a sensitive biomarker of glomerular function.
Penkid is a 5-kDa peptide derived from the same pre-
cursor as met- and leu-enkephalins and is considered a
stable surrogate marker for the unstable enkephalins.9
Although numerous functions of enkephalins have been
described, including stimulation of kidney function,10
penkid might be a “connecting peptide” in the precur-
sor only, presumably without a function in the blood
circulation. There is no evidence for penkid being
possibly protein bound, as linearity and recovery in the
penkid assay have been found to be not impaired. Pro-
enkephalin A is expressed in number of tissues,11
including the kidney and the heart. Plasma concentra-
tions of penkid have been found to be strongly nega-
tively correlated with measured glomerular ﬁltration rate
(GFR),12 and thus penkid is considered a marker of kid-
ney function (not damage). Upon acute kidney dysfunc-
tion, penkid levels increase more quickly than
creatinine.13 Increase of plasma penkid appears to be
highly speciﬁc for kidney dysfunction; in contrast to
other markers, it is not inﬂuenced by nonkidney-
related variables such as, for instance, systemic inﬂam-
mation. However, conﬁrmation of these promising results
is warranted.
In the present study, we have investigated whether
penkid levels are associated with MAKEs, as well as
AKI and WRF in ICU patients with severe sepsis or
septic shock.
METHODS
Study Design
The Kid-SSS study was an ancillary investigation of the
AdrenOSS study, a European prospective, observa-
tional, multinational study in 24 centers from 5 coun-
tries (France, Belgium, the Netherlands, Italy, and
Germany). Patients were recruited from June 2015 to
May 2016. The study protocol was approved by the
local ethical committees and conducted in accordance
with Directive 2001/20/EC, as well as Good Clinical
Practices (I.C.H. version 4 of May 1, 1996 and Decision
of November 24, 2006) and the Declaration of Helsinki.
Patients were enrolled who were 18 years and older
and who were (i) admitted to the ICU for sepsis or septic
shock14 or (ii) transferred from another ICU in the state
of sepsis and septic shock within less than 24 hours after
primary admission. If patients were treated with vaso-
pressors, they were considered eligible only if treatment
had been started within a maximum of 24 hours after the
primary admission before ICU admission.When patients
were included, they were stratiﬁed by severe sepsis and
septic shock based on the deﬁnitions for sepsis and or-
gan failure from 2001.15 Exclusion criteria were preg-
nancy, vegetative coma, and participation in an
interventional trial in the preceding month. Informed
consent was obtained from all patients or their lawful
representatives prior to enrollment in the study. Pa-
tients were treated according to current guidelines, and
all treatments and procedures were registered. Blood for
the assessment of penkid was drawn on days 0, 1, and 2.
A subset of patients (n¼ 536) from the FROG-ICU study
with severe sepsis (n ¼ 48) or septic shock (n ¼ 488) was
used as a validation cohort. The FROG-ICU study was a
prospective, observational, multicenter cohort study
designed to investigate long-term mortality of critically ill
adult patients. The study was performed in accordance
with Good Clinical Practice and the Declaration of Helsinki
of 2002, validated by the corresponding ethical commit-
tees, and registered on ClinicalTrials.gov (NCT01367093).
The protocol of the FROG-ICU study was previously
published.16
The primary endpoint of the Kid-SSS investigation
was MAKE at day 7. The secondary endpoints con-
sisted of the assessment of AKI, transient AKI, WRF,
and 28-day mortality.
Endpoint Deﬁnitions
Major adverse kidney events included death, need for
renal replacement therapy (RRT), and persistent AKI by
day 7. Acute kidney injury was deﬁned using the Kid-
ney Disease: Improving Global Outcomes (KDIGO)
criteria.17 Baseline serum creatinine (Screat) was
assessed using the following method: If estimated
glomerular ﬁltration rate (eGFR) on admission was $75
ml/min per 1.73 m2, we used the actual SCreat on
admission (admission SCreat). If eGFR was <75 ml/min
per 1.73 m2 on admission, we used the SCreat calculated
back from the Modiﬁcation of Diet in Renal Disease
Study (MDRD) equation set to 75 ml/min per 1.73 m2.
Persistent AKI was deﬁned as an elevated SCreat
level from baseline by >1.5-fold or $0.3 mg/dl (26.5
mmol/l) at day 7 (or discharge, if earlier), or RRT at day
7, or death within 7 days after ICU admission.
WRF opposes transient AKI and was deﬁned as an
increase in serum creatinine level by $1.5-fold or $0.3
mg/dl (26.5 mmol/l), or need for RRT, or death within
A Hollinger et al.: Penkid Predicts Course of Renal Function in Septic Patients CLINICAL RESEARCH
Kidney International Reports (2018) 3, 1424–1433 1425
48 hours from admission, all representative of poor
clinical evolution.
Transient AKI was deﬁned by the highest value of
admission SCreat measured during the ﬁrst 48 hours
after ICU admission, decreasing thereafter without need
for RRT at any time.
Chronic kidney disease (CKD) was deﬁned as known
history of kidney disease.
Because prediction of kidney events may be
hampered in patients with already-high Screat upon
admission, we performed an analysis of 3 subgroups in
patients with eGFR>75 ml/min per 1.73 m2, renal SOFA
score of 0, and renal SOFA score of#1 on admission. The
subgroup identiﬁed as “low Screat at admission” was
deﬁned as patients with renal SOFA score of 0 at
admission.
Collection of Patient Data
Upon admission, demographics (age, gender), body
mass index, presence of sepsis or septic shock, type of
ICU admission, organ dysfunction scores (Sequential
Organ Failure Assessment [SOFA], Acute Physiology
And Chronic Health Evaluation II [APACHE II] score),
the source of sepsis, pre-existing comorbidities treated
within the past year, past medical history, laboratory
values, urine output, as well as organ support were
recorded.
During the ﬁrst week after patient enrollment, the
following data were assessed and/or collected on a daily
basis: SOFA score, antimicrobial therapies, ﬂuid bal-
ance, ventilation status, Glasgow Coma Scale score,
central venous pressure, need for RRT, invasive pro-
cedures for sepsis control, and vasopressor treatment.
On day 28, discharge status or mortality was recorded
in all study participants.
Measurement of Penkid
Blood for the central laboratory was sampled within 24
hours after admission for penkid measurement. Sam-
ples were subsequently processed and stored at 80 C
before transfer to the central laboratory for the blinded
penkid analysis organized by the study sponsor
(Sphingotec GmbH, Hennigsdorf, Germany). The mea-
surements were performed in batch within 3 months
after recruitment of the last patient based on a docu-
mented real-time stability of almost 2 years. Penkid was
measured in duplicate using a chemiluminescence
immunoassay (Sphingotec GmbH, Hennigsdorf, Ger-
many), as described previously.18 The lower detection
limit of the immunoassay was 5.5 pmol/l. Intra-assay
and interassay coefﬁcients of variation were 6.4%
and 9.5% at 50 pmol/l, and 4.0% and 6.5% at 150
pmol/l, respectively. As in previous publications,
coefﬁcients of variation are reported here only for 2
samples in concentration ranges of special interest,
namely, in the low range (50 pmol/l is close to the
median of a normal reference population) and for a
moderately elevated concentration (150 pmol/l). Intra-
assay and interassay precision proﬁles of the assay
have been determined with many more samples
covering the entire measuring range of the assay. As
expected for sandwich immunoassay, the proﬁles are of
continuous shape: Concentrations >150 pmol/l until
the upper end of the calibration curve (w2500 pmol/l)
are detected with a precision similar to that reported
for the 150-pmol/l sample; concentrations between 150
and 50 pmol/l are detected with a precision between
those determined for the 150- and 50-pmol/l samples;
and the coefﬁcient of variation for concentrations <50
pmol/l increases at lower concentrations.
Statistical Analyses
Values are expressed as means and SDs, medians and
interquartile ranges (IQRs), or counts and percentages,
as appropriate. Group comparisons of continuous var-
iables were performed using the KruskalWallis test.
Data for penkid, Screat, eGFR, and urine output, as
well as lactate, were log transformed. Categorical data
were compared using the Pearson’s Chi-squared test.
Logistic regression was used to evaluate penkid for the
different endpoints, both for univariable and multi-
variable analyses. To demonstrate independence from
clinical variables already known, the added value of
penkid on top of these variables was evaluated based
on the likelihood ratio c2 test for nested models. The
concordance index (C index or AUC) is given as an
effect measure for univariable and multivariable
models. For multivariable models, a bootstrap corrected
version of the C index is given. For continuous vari-
ables, odds ratios (ORs) were standardized to describe
the OR for a change of 1 IQR. Ninety-ﬁve percent CIs
for risk factors and signiﬁcance levels for c2 are given.
For illustration, receiver operating characteristic curves
were constructed to assess the sensitivity and speci-
ﬁcity of penkid to predict the kidney endpoints.
Cox proportional hazards regression was used to
analyze the effect of risk factors on survival in uni-
variable and multivariable analyses. Methods similar to
those described for logistic regression were applied.
Survival curves plotted by the KaplanMeier method
were used for illustrative purposes. We also explored
association between penkid and 28-day mortality. The
cut-off of 84 pmol/l was used as the median value of
penkid in the cohort. Of note, the cut-off was close to
the upper limit of normal of penkid previously
reported.
Missing data were not replaced. All statistical tests
were 2-tailed, and a 2-sided P value of 0.05 was
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considered signiﬁcant. The statistical analyses were
performed using R version 2.5.1 (http://www.r-project.
org, library Design, Hmisc, ROCR) and the Statistical
Package for the Social Sciences (SPSS) version 22.0
(SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
A total of 583 patients were included in the study.
Patient characteristics on admission with respect to the
primary endpoint or penkid quartiles are presented in
Table 1 and Supplementary Table S1 (see also
Supplementary Appendix S1). Median age was 66 years
(range, 55–75 years); 62% of patients were male; the
median Simpliﬁed Acute Physiology Score (SAPS II)
was 50 (range, 39–63), and the 28-day mortality was
22% (95% conﬁdence interval [CI] ¼ 19%–25%). Of
the patients, 293 (50.3%) were in shock upon ICU
admission. Penkid increased with increasing renal
SOFA scores (P < 0.0001). Patients with a renal SOFA
score of 0 had a median penkid concentration of 53.7
pmol/l (IQR ¼ 39.2–73.6 pmol/l), similar to that of a
healthy reference population.19 Outcome data for the
overall median penkid value of 84.2 pmol/l are sum-
marized in Supplementary Table S2.
Of the 536 severe sepsis and septic shock patients,
penkid was measured in 532 patients on ICU admission.
Of those, MAKEs and AKI were possible to determine
in 525 patients, and WRF was possible to evaluate in
496 patients. The FROG-ICU cohort included 525 pa-
tients with severe sepsis or septic shock. The charac-
teristics of the patients in the validation cohort are
presented in Supplementary Table S3.
Prediction of Kidney Events with Penkid
The median penkid concentration at admission in all
studied patients was 84 pmol/l (IQR¼ 53–156 pmol/l) in
the AdrenOSS cohort and 85 pmol/l (IQR ¼ 46–156.3
pmol/l) in the FROG-ICU cohort (Table 1 and
Supplementary Table S3). When investigating MAKEs
as a combined endpoint after 7 days in the 579 patients
with the available data in the AdrenOSS cohort, 67 pa-
tients had died, 51 patients were alive with need of RRT
at some point during the ﬁrst 7 days, and 51 were alive
with persistent AKI without having received RRT.
Accordingly, a total of 169 events were recorded in this
study population. Patients who developedMAKEs had a
higher penkid concentration at admission compared to
patients without MAKEs (median 65, IQR¼ 45–106, vs.
median 179, IQR ¼ 114–242, P < 0.0001) (Figure 1).
Likewise, penkid concentrations were signiﬁcantly
higher in patients with AKI and who developed WRF
(median 53, IQR¼ 39–70, vs. median 133, IQR¼ 79–196
pmol/l, P < 0.0001, and median 70, IQR ¼ 47–121, vs.
median 174, IQR ¼ 93–242, pmol/l, P < 0.0001 respec-
tively). Similar results were observed in the validation
cohort (Supplementary Figure S1). Also, penkid showed
a stepwise increase with AKI severity (Supplementary
Figure S2) and was also elevated in patients who
received RRT within the ﬁrst 7 days (median 74, IQR ¼
48–134, vs. median 176, IQR ¼ 102–265 pmol/l, P <
0.0001) (Figure 1). Penkid concentration on admission
was independently associated with MAKE in the stud-
ied population. The association remained signiﬁcant
after adjustment for potential confounding factors
including age, gender, admission diagnosis, history of
CKD, history of diabetes, history of hypertension, urine
output, and eGFR on admission (adjusted standardized
OR ¼ 3.3 [95% CI ¼ 1.8–6.0], P < 0.0001) (Figure 2).
Similarly, penkid concentration on admission was
signiﬁcantly associated with the risk of AKI and WRF,
even after adjustment for confounding variables
(adjusted standardized OR¼ 3.9 [95% CI¼ 2.1–7.2] and
3.4 [1.9–6.2]). The same was true for the FROG-ICU vali-
dation cohort (Supplementary Figure S3), only here it was
not possible to adjust for urine output and admission
diagnosis. Likewise, penkid at admission was also signif-
icantly associated with the risk of RRT in the AdrenOSS
cohort, albeit not after adjustment (adjusted standardized
OR 1.9 [95% CI ¼ 0.95–3.7], P ¼ 0.069).
Predictive Value of Penkid According to Baseline
Kidney Function
To illustrate the added value of penkid over Screat,
Figure 3 shows the incidence of MAKEs and WRF ac-
cording to penkid concentration <84 pmol/l or >84
pmol/l at admission across the renal component of the
SOFA score. Figure 3 shows that patients in almost any
renal SOFA score subgroup had a higher rate of MAKE
and WRF when their penkid concentration was >84
pmol/l than when penkid was #84 pmol/l.
When restricting the analysis to patients with low
Screat at admission (renal SOFA score #1, renal SOFA
score 0 or eGFR >75) or patients without CKD, penkid
was signiﬁcantly associated with kidney events, and
was more discriminant than Screat for their prediction
(Table 2).
A total of 76 patients had a history of CKD and
showed statistically signiﬁcantly higher penkid con-
centrations at admission (median 206, IQR ¼ 135–318,
versus median 74, IQR ¼ 48–133, pmol/l, P < 0.0001).
Penkid concentrations predicted both MAKE and WRF
in both patients with and without CKD (MAKE: AUC ¼
0.794, 95% CI ¼ 0.686–0.902, and AUC ¼ 0.818, 95%
CI ¼ 0.774–0.862; WRF: AUC ¼ 0.775, 95% CI ¼
0.672–0.879, and AUC ¼ 0.755, 95% CI ¼ 0.703–0.808).
Serial measurement (i.e., at admission, day 1, and
day 2 for MAKE and at admission and day 1 for WRF)
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(Figure 4) of penkid improved the predictive value
for MAKE and WRF (added value P < 0.05 for both,
AUC increase from 0.838 to 0.851 and 0.778 to 0.790
for endpoint MAKE and WRF, respectively; AUCs for
multivariable models were bootstrap corrected). The
gain was more pronounced for patients with renal
SOFA #1 (added value P < 0.05 for both, AUC in-
crease from 0.749 to 0.774 and 0.715 to 0.743 for
endpoint MAKE and WRF, respectively).
Finally, we investigated whether low penkid con-
centration can indicate an improvement of renal func-
tion. In patients with AKI upon admission, penkid was
superior to SCreat in detecting those patients likely to
recover early from AKI, hence predicting transient AKI
(Supplementary Figure S4) (AUC ¼ 0.649, 95% CI ¼
0.603–0.695; AUC ¼ 0.554, 95% CI ¼ 0.506–0.603; and
AUC ¼ 0.559, 95% CI ¼ 0.510–0.606 for penkid,
SCreat, and eGFR; penkid adjusted standardized OR ¼
0.36, 95% CI ¼ 0.22–0.59).
Levels of Penkid and 28-Day Mortality
Over a 28-day follow-up period, 127 patients (22%)
died. High penkid concentration on admission was
associated with worse outcome in both cohorts
(Figure 5a, b). In the univariate Cox regression, the C-
index for prediction of 28-day mortality for penkid at
admission was 0.661 (95% CI ¼ 0.615–0.701, P <
0.0001). The C-index for creatinine, eGFR, and age was
Table 1. Patient characteristics
All No MAKE MAKE P value
Characteristics N ¼ 579 n ¼ 410 (70.8%) n ¼ 169 (29.2%)
Penkid at admission (pmol/l) 83.4 [52.7–154.0] 64.7 [44.9–106.0] 178.6 [113.7–241.9] <0.0001
Age (yr) 65.6 [55–75.4] 64.4 [54.0–74.0] 69.4 [59.5–77.1] 0.0013
Males, n (%) 361 (62.3) 258 (62.9) 103 (60.9) 0.7243
Septic shock at admission (yes) 292 (50.4) 171 (58.3) 121 (71.6) 0.0005
Medical history
Cardiac comorbidity 396 (68.4) 257 (62.7) 139 (82.2) <0.0001
Noncardiac comorbidity 410 (70.8) 282 (68.8) 128 (75.7) 0.1155
CKD 76 (13.0) 28 (6.8) 47 (27.8) <0.0001
Hypertension 290 (50.1) 187 (45.6) 103 (60.9) 0.0007
Diabetes melitus 158 (27.3) 99 (24.1) 59 (34.9) 0.0121
Physiological values at admission
Mean blood pressure (mm Hg) 75 [64–90] 76 [65–93] 73 [61–86] 0.0271
Heart rate (bpm) 104 [90–119] 104 [90–119] 103 [88–117] 0.6996
Fluid balance (ml) 1930 [600–3561] 1655 [430–3108] 2787 [1263–4685] <0.0001
PaO2/FiO2 224 [137–340] 221 [138–343] 234 [136–333] 0.8092
Laboratory values at admission
Lactate 2.4 [1.49–4] 2.2 [1.4–3.3] 3.65 [1.72–7.77] <0.0001
Arterial pH 7.38 [7.3–7.44] 7.4 [7.33–7.45] 7.32 [7.25–7.4] <0.0001
Bilirubin (mmol/l) 11 [6–19] 11 [7–19] 11 [6–21] 0.6286
Platelets (109/l) 190 [120–275] 196 [125–287] 168 [103–259] 0.0269
Creatinine (mg/dl) 1.35 [0.86–2.22] 1.1 [0.75–1.61] 2.64 [1.7–4.05] <0.0001
BUN or urea (mg/dl) 61.3 [37.1–107.3] 51.0 [33.2–81.1] 107.5 [61.3–144.1] <0.0001
Hematocrit (%) 34 [29–38] 35 [30–38] 33 [28–38] 0.1342
White blood cell count (/mm3) 12,455 [7185–18,520] 12,970 [7625–18,800] 11,325 [5790–17,000] 0.0785
Organ support at admission
Mechanical ventilation <0.0001
Invasive 219 (37.8) 132 (32.2) 87 (51.5)
Noninvasive 128 (22.1) 106 (25.9) 22 (13)
None 232 (40.1) 172 (42) 60 (35.5)
Renal replacement therapy 49 (8.5) 0 (0) 49 (29) <0.0001
Vasopressor at admission 336 (58) 205 (50) 131 (77.5) <0.0001
Organ dysfunction scores
SOFA (points) 7 [5–10] 6 [4–9] 10 [8–13] <0.0001
APACHE II (points) 15 [11–20] 14 [10–18] 19 [15–23] <0.0001
Length of stay (d)
ICU 5 [2–9] 6 [3–10] 3 [2–7] <0.0001
Mortality (%)
28-Day, deaths 126 (21.8) 51 (12.4) 75 (44.4) <0.0001
90-Day, deaths 165 (28.5) 75 (18.3) 90 (53.3) <0.0001
APACHE II, Acute Physiology And Chronic Health Evaluation II; BUN, blood urea nitrogen; CKD, chronic kidney disease; ICU, intensive care unit; MAKE, major adverse kidney event;
SOFA, Sequential Organ Failure Assessment.
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0.589 (95% CI ¼ 0.542–0.636, P ¼ 0.00561), 0.589
(95% CI ¼ 0.542–0.636, P ¼ 0.00503), and 0.603 (95%
CI ¼ 0.554–0.651, P < 0.0001), respectively. In a Cox
proportional-hazard model adjusted for age, gender,
comorbidities (cardiac and noncardiac), lactate,
creatinine, and diagnosis (sepsis, septic shock), penkid
concentration on admission was independently asso-
ciated with 28-day mortality (P < 0.002 for added
value, adjusted standardized hazard ratio ¼ 1.9 [95%
CI ¼ 1.3–2.9]). Penkid was also independent from
Figure 2. Standardized odds ratio (OR) for proenkephalin A 119-159 (penkid) from the Adrenomedullin and Outcome in Severe Sepsis and Septic
Shock (AdrenOSS) cohort, unadjusted (unadj.) and adjusted (adj.) for age, sex, admission diagnosis, history of chronic kidney disease, history of
diabetes, history of hypertension, urine output, and estimated glomerular ﬁltration rate on admission, and in patients with low creatinine (i.e.,
renal Sequential Organ Failure Assessment [SOFA] #1 [other subgroups not reported due to low event numbers]); endpoints major adverse
kidney events (MAKEs), worsening renal function (WRF), and acute kidney injury (AKI). Odds ratios are standardized to 1 interquartile range
(IQR); all P < 0.05.
Figure 1. Proenkephalin A 119-159 (penkid) values from the Adrenomedullin and Outcome in Severe Sepsis and Septic Shock (AdrenOSS)
cohort at admission (boxplots) in (a) patients with or without major adverse kidney events (MAKEs) at day 7, (b) patients with acute kidney injury
(AKI) and patients without, (c) patients with worsening renal function (WRF) and patients without, and (d) patients with or without renal
replacement therapy (RRT).
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SOFA and APACHE score (both p<0.05 for added
value).
DISCUSSION
In the prospective, multinational, observational Kid-
SSS study, we showed that elevated levels of penkid
upon admission were independently associated with
kidney events and death in septic and septic shock
patients. Penkid was further prognostic for kidney
events in patients presenting with low serum creatinine
on admission and transient AKI. These ﬁndings were
consistently observed in another validation cohort of
525 patients with severe sepsis or septic shock.
Previous investigations had already suggested that
penkid could be a dynamic biomarker of kidney
function, and that an initial measurement would allow
an estimation of early patient survival.5
Current deﬁnitions of AKI have been based on serum
creatinine and urine output. Both of these biomarkers,
however, have limits in their sensitivity and speci-
ﬁcity.6,20 Although there are no doubts that oliguric
patients or patients with high serum creatinine present
with worse prognoses, these biomarkers may introduce
delay in recognizing AKI.21 One major point is the
physiological behavior of Screat, which rises after the
decrease in glomerular ﬁltration rate due to the high
volume of distribution.3,22 Septic patients are even
more exposed to these limitations due to the decrease in
creatinine production and the large volume of ﬂuid that
they receive. Therefore, the value of a more sensitive
biomarker of AKI would be to detect early changes in
GFR before Screat has risen. In this line, looking at the
subcategories of the renal component of the SOFA score
gives us the opportunity to explore the potential value
Table 2. Overview of predictive performance of penkid and Screat in patients with low serum creatinine (i.e., SOFA score ¼ 0) at admission
Endpoint Subgroup n Events Event rate
AUC Added value of penkid
Screata penkida P value
MAKE All 579 169 29% 0.831 [0.795, 0.867] 0.838 [0.802, 0.874] <0.001
No CKD 500 121 24% 0.815 [0.771, 0.859] 0.818 [0.774, 0.862] <0.001
eGFR >75 180 7 4% 0.504b[0.246, 0.722] 0.700 [0.480, 0.905] 0.048
SOFA ¼ 0 212 13 6% 0.637b[0.459, 0.811] 0.779 [0.639, 0.919] <0.001
SOFA ¼ 0/1 336 37 11% 0.704 [0.617, 0.793] 0.749 [0.665, 0.832] <0.001
AKI All 582 360 62% 0.948 [0.929, 0.967] 0.854 [0.823, 0.884] <0.001
No CKD 502 284 57% 0.936 [0.912, 0.959] 0.826 [0.791, 0.862] <0.001
eGFR >75 180 18 10% 0.627 [0.453, 0.800] 0.624b[0.484, 0.762] 0.052
SOFA ¼ 0 212 30 14% 0.621b[0.483, 0.755] 0.736 [0.634, 0.839] <0.001
SOFA ¼ 0/1 337 138 41% 0.898 [0.858, 0.939] 0.761 [0.709, 0.813] <0.001
WRF All 576 142 25% 0.734 [0.688, 0.781] 0.778 [0.733, 0.822] <0.001
No CKD 497 106 21% 0.714 [0.660, 0.768] 0.755 [0.703, 0.808] <0.001
eGFR >75 178 10 6% 0.539b[0.341, 0.752] 0.694 [0.506, 0.880] 0.032
SOFA ¼ 0 209 16 8% 0.485b[0.286, 0.618] 0.739 [0.608, 0.873] <0.001
SOFA ¼ 0/1 334 40 12% 0.649 [0.555, 0.741] 0.715 [0.631, 0.799] <0.001
AKI, acute kidney injury; AUC, area under the curve; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; penkid, proenkephalin A 119-159; Screat, serum creatinine;
SOFA, Sequential Organ Failure Assessment; WRF, worsening renal function.
aAUC with 95% confidence intervals.
bP > 0.05; all other univariate P < 0.05.
Figure 3. Bar graphs showing incidence of (a) major adverse kidney events (MAKEs) and (b) worsening renal function (WRF) with respect to
proenkephalin A 119-159 (penkid) concentration upon admission above or below the predeﬁned cut-off value of 84.2 pmol/l (population median)
across renal Sequential Organ Failure Assessment (SOFA) score stage on admission. Median serum creatinine (Screat) values are 0.8, 1.5, 2.6,
2.7, and 2.6 mg/dl for renal SOFA score categories 0, 1, 2, 3, and 4, respectively.
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of penkid in patients with low Screat at admission. In
other words, early prediction of AKI in patients already
presenting with high Screat makes little sense, and the
potential additional value of the biomarker for AKI
prediction lies in patients with low Screat.
Furthermore, the pathophysiology of septic AKI is
complex and multifactorial. Regional immune response
and inﬂammatory response, cellular dysfunction, and
microcirculatory failure are proposed as the key con-
tributors to septic AKI.23–25 The use of AKI biomarkers
cross-reacting with the inﬂammatory response may
therefore limit their value in predicting AKI in a septic
condition. It appears that penkid is not directly
affected by the inﬂammatory response, as penkid
concentrations in patients without AKI are within the
normal range. Therefore, penkid could be more speciﬁc
in septic AKI than biomarkers affected by the systemic
inﬂammatory response.20,26
Previous ﬁndings suggest that a time-sensitive
biomarker of GFR, being independent of inﬂamma-
tion, could therefore provide added value in septic
AKI, which has led to the investigation of penkid in
our study.
A substantial number of septic patients already pre-
sented to the ICU with AKI and high Screat. The clinical
value of penkid may therefore be limited to predict AKI.
However, we showed that penkid anticipated WRF in
patients presenting with low Screat on admission and
could therefore represent an early biomarker of septic
AKI. Furthermore, penkid was prognostic for MAKEs
and death in these patients, even after adjustment for
confounding variables. On the other hand, low penkid
was suggestive for rapid renal recovery (i.e., transient
AKI).
Previously, it has been detected that opioid re-
ceptors are strongly expressed in the kidney,27 and
Figure 5. Twenty-eight-day KaplanMeier survival curves of low versus high proenkephalin A 119-159 (penkid) concentrations at admission, (a)
based upon the cut-off value of 84.2 pmol/l (population median) in all patients from the Adrenomedullin and Outcome in Severe Sepsis and
Septic Shock (AdrenOSS) study cohort, and (b) based upon the cut-off value of 85 pmol/l (population median) in all patients from the French and
euRopean Outcome reGistry in Intensive Care Units (FROG-ICU) study cohort.
Figure 4. Proenkephalin A 119-159 (penkid) at admission, day 1, and day 2 in patients with low serum creatinine (renal Sequential Organ Failure
Assessment [SOFA] score of 0 or 1) upon admission (a) according to worsening renal function (WRF) occurrence and (b) according to major
adverse kidney events (MAKEs).
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that opioid agonists could stimulate kidney function4;
therefore, penkid was further investigated as a
biomarker for the assessment of kidney function and
prediction of development of AKI. It was suggested
that penkid could determine kidney function in a more
accurate and timely manner when compared to
Screat.28 Moreover, penkid has exhibited promising
features in monitoring kidney function in acutely ill
patients, including septic patients.26 In patients with
acute heart failure, penkid adds value to the surveil-
lance of kidney function in addition to the reﬂection of
cardiorenal status after acute myocardial infarction18
and prediction of AKI in the postoperative cardiac
surgery setting.13
Limitations of the present study are that the present
population included patients with severe sepsis and
septic shock before the release of the new Sepsis-3
deﬁnition. As such, results cannot be directly trans-
lated to the new deﬁnition, even though the deﬁnition
remains close. Future studies should focus on extrap-
olation of our results to patients with the new deﬁni-
tion. Second, our ﬁndings were not investigated
prospectively in a validation cohort. Third, inulin
clearance remains the gold standard for the assessment
of kidney function, but was not investigated in this
study. Also, penkid was not compared to alternative
biomarkers of glomerular/tubular function (e.g., cys-
tatin C, neutrophil gelatinase-associated lipocalin
[NGAL]), nor was it compared to biomarkers of kidney
injury (e.g., NGAL, kidney injury molecule-1 [KIM-1],
liver-type fatty acid-binding protein [L-FABP], or
TIMP2*IGFBP7, except from a subset of FROG-ICU, in
which penkid has been compared with TIM-
P2*IGFBP727). Fourth, the uniethnicity of the studied
population may impede translation of the study results
to a multiethnic population. Finally, we acknowledge
that impact of early recognition of AKI and prediction
of AKI on treatment and patient outcomes remains
elusive, even though a recent study suggested that
early intervention might improve renal outcomes.29,30
In conclusion, in a large, prospective, international
cohort of critically ill patients with sepsis and septic
shock (Kid-SSS), penkid was predictive of septic kid-
ney events including MAKEs, AKI, WRF, and renal
recovery, which was validated in an independent large
cohort, FROG-ICU.
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SUPPLEMENTARY MATERIAL
Figure S1. Penkid values from the FROG-ICU cohort at
admission (boxplots) in (A) patients with or without major
adversekidneyevents (MAKEs)atday7, (B)patientswithacute
kidney injury (AKI) and patients without, (C) patients with
worsening renal function (WRF) and patients without, and (D)
patients with or without renal replacement therapy (RRT).
Figure S2. Penkid values at admission (boxplot) according
to AKI staging (P < 0.001).
Figure S3. Standardized odds ratio for penkid from the
FROG-ICU cohort, unadjusted and adjusted for age, sex,
history of CKD, history of diabetes, history of hypertension
and eGFR on admission, and in patients with low creati-
nine (i.e., renal SOFA #1); endpoints MAKE, WRF and AKI.
OR are standardized to 1 IQR; all P < 0.05.
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Figure S4. Penkid values at admission (boxplot) according
to rapid recovery from AKI and transient AKI (P < 0.001).
Table S1. Patient characteristics of the AdrenOSS cohort
displayed in quartiles.
Table S2. Outcome data based on median penkid value of
84.2 pmol/l.
Table S3. Patient characteristics from the FROG-ICU cohort.
Appendix S1. Listing of Site Investigators for the
AdrenOSS study.
Supplementary material is linked to the online version of
the paper at www.kireports.org.
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